Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine has gained importance in the treatment of AML, with important developments in gene mutation-targeted therapeutic agents transforming the treatment landscape. The role of measurable residual disease (MRD), an independent, postdiagnosis, prognostic indicator, in AML has been explored for many years. Still, the implementation of standardized MRD techniques remains critical for their use in clinical practice. Although the field has seen major therapeutic advances, novel agents, targets, and regimens continue to be investigated to offer patients a more promising outcome.

In this VJSession, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, is joined by Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, and Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, who discuss the exciting updates in the field of AML from the 2021 EHA and ASCO meetings, including developments in targeted therapeutic agents, MRD approaches and emerging therapies and targets.